Travere Therapeutics (TVTX) Notes Payables (2011 - 2017)
Travere Therapeutics' (TVTX) quarterly Notes Payables came in at $15.7 million in Q4 2017, down 29.99% YoY from $22.4 million in Q4 2016, and down 22.0% on a QoQ basis from $20.1 million in Q3 2017.
Travere Therapeutics (TVTX) Notes Payables (2011 - 2017) Analysis & Trends
Travere Therapeutics (TVTX) has 7 years of Notes Payables data on file, last reported at $15.7 million in Q4 2017.
- Quarterly Notes Payables fell 29.99% year-over-year to $15.7 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $15.7 million (down 29.99% YoY) and the FY2017 annual result came in at $15.7 million, down 29.99% from the prior year.
- Notes Payables eased to $15.7 million in Q4 2017, from $20.1 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $91.2 million in Q2 2015 to a low of $10000.0 in Q1 2013.
- A 5-year average of $29.2 million and a median of $24.5 million in 2016 frame the typical range for Notes Payables.
- Annual changes were most pronounced in 2014 — Notes Payables surged 184700.0% — and 2016, when it tumbled 63.42%.
- Tracing TVTX's Notes Payables over 5 years: stood at $25.0 million in 2013, then rose by 11.79% to $28.0 million in 2014, then soared by 38.66% to $38.8 million in 2015, then sank by 42.18% to $22.4 million in 2016, then slipped by 29.99% to $15.7 million in 2017.
- The last three Notes Payables figures came in at $15.7 million (Q4 2017), $20.1 million (Q3 2017), and $22.5 million (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 15.71 Mn |
| Sep 30, 2017 | 20.14 Mn |
| Jun 30, 2017 | 22.46 Mn |
| Mar 31, 2017 | 21.18 Mn |
| Dec 31, 2016 | 22.44 Mn |
| Sep 30, 2016 | 28.96 Mn |
| Jun 30, 2016 | 33.36 Mn |
| Mar 31, 2016 | 24.47 Mn |
| Dec 31, 2015 | 38.81 Mn |
| Sep 30, 2015 | 42.12 Mn |
| Jun 30, 2015 | 91.20 Mn |
| Mar 31, 2015 | 63.39 Mn |
| Dec 31, 2014 | 27.99 Mn |
| Sep 30, 2014 | 18.48 Mn |
| Dec 31, 2013 | 25.04 Mn |
| Sep 30, 2013 | 10,000.00 |
| Mar 31, 2013 | 10,000.00 |
| Nov 30, 2012 | 9,572.00 |
| Feb 29, 2012 | 9,572.00 |
| Nov 30, 2011 | 25.00 Mn |